Ragni Enrico, De Luca Paola, Landoni Simona, Valli Federico, Mortati Leonardo, Palombella Silvia, Talò Giuseppe, Moretti Matteo, de Girolamo Laura
IRCCS Istituto Ortopedico Galeazzi, Laboratorio di Biotecnologie Applicate all'Ortopedia, Via Cristina Belgioioso 173, 20157 Milano, Italy.
IRCCS Istituto Ortopedico Galeazzi, Chirurgia Articolare Sostitutiva e Chirurgia Ortopedica (C.A.S.C.O.), Via Cristina Belgioioso 173, 20157 Milano, Italy.
Regen Ther. 2024 Jul 7;26:442-457. doi: 10.1016/j.reth.2024.06.020. eCollection 2024 Jun.
Extracellular vesicles from mesenchymal stromal cells (MSC-EVs) are potent stimulators of naïve cartilage and their injection is studied in clinical trials for cartilage lesions, since often cartilage repaired with conventional approaches is incomplete or less performant leading to joint degeneration. The main pitfall of these innovative approaches is the high EVs dispersion into the joint cavity and consequent low concentration at lesion site. Thus, biological scaffolds for concentration of EVs where needed might be a promising option. This work aimed at producing an enhanced platelet-derived fibrin gel loaded with adipose-derived MSCs (ASCs)-EVs.
EVs' embedment efficiency in platelet gel, their release and incorporation in OA chondrocytes and cartilage explants were monitored by flow cytometry, microfluidic approaches, scansion electron microscopy and real-time quantitative multimodal nonlinear optics imaging. The effect of released EVs was tested in OA chondrocytes by gene expression studies.
A protocol ensuring high incorporation EVs efficiency in platelet gels was defined, relying on a one-step modification of the standard procedure used in current clinical practice. Trapped EVs were released continuously for up to 4 weeks and uptaken in pathologic chondrocytes and cartilage explants. The release of the EVs-loaded platelet gel had stronger and synergic anti-inflammatory/matrix remodelling effects with respect to both EVs per se and unloaded gel released products.
These results suggest the feasibility of producing a platelet gel loaded with MSC-EVs at high efficiency that can be used as an enhanced tool to foster chondrocyte homeostasis, a key requisite for proper cartilage healing.
间充质基质细胞来源的细胞外囊泡(MSC-EVs)是幼稚软骨的有效刺激物,目前正在针对软骨损伤的临床试验中研究其注射应用,因为传统方法修复的软骨往往不完整或性能较差,会导致关节退变。这些创新方法的主要缺陷是细胞外囊泡在关节腔内高度分散,导致损伤部位的浓度较低。因此,在需要时用于浓缩细胞外囊泡的生物支架可能是一个有前景的选择。本研究旨在制备一种负载脂肪来源间充质干细胞(ASCs)-细胞外囊泡的强化血小板衍生纤维蛋白凝胶。
通过流式细胞术、微流控方法、扫描电子显微镜和实时定量多模态非线性光学成像监测细胞外囊泡在血小板凝胶中的包埋效率、释放情况以及在骨关节炎软骨细胞和软骨外植体中的掺入情况。通过基因表达研究在骨关节炎软骨细胞中测试释放的细胞外囊泡的作用。
确定了一种确保细胞外囊泡在血小板凝胶中高掺入效率的方案,该方案依赖于对当前临床实践中使用的标准程序进行一步修改。捕获的细胞外囊泡持续释放长达4周,并被病理软骨细胞和软骨外植体摄取。与细胞外囊泡本身和未负载凝胶释放的产物相比,负载细胞外囊泡的血小板凝胶的释放具有更强的协同抗炎/基质重塑作用。
这些结果表明高效制备负载MSC-EVs的血小板凝胶是可行的,该凝胶可用作促进软骨细胞稳态的强化工具,而软骨细胞稳态是软骨正确愈合的关键条件。